
Cue Biopharma, Inc.: quarterly results
Price
$14.10
November 16, 2026Market cap $102M
What Ploutos Investor adds for Cue Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 53% since Aug 14, 2026, when the 10-Q these figures come from was filed ($34.20 then, $16.12 on Nov 13, 2026). The figures date from before that move.10-Q
Results, quarter by quarter
When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.
Next results
last Nov 16, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
The first session after results
±13.7%average move, either way
0 times upof the last 33 times down
Largest: -19.2% on Aug 17, 2026 (Q2 2026).
How the stock moved after each release
The close of the first session after the results against the close before them.
CUE that sessionS&P 500 the same day
Every release
Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.
- Q3 2026Stock, next session–
- Q2 2026Stock, next session-19.2%
- Q1 2026Stock, next session-9.2%
- Q4 2025Stock, next session-12.8%
| Quarter | Released | Revenue | EPS | Stock, next session | S&P 500 | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 16, 2026 | with the 10-Q | with the 10-Q | – | – | 8-K |
| Q2 2026 | Aug 14, 2026after the close | $7.9M+166.7% | -$24.14 | -19.2% | -0.5% | 8-K |
| Q1 2026 | May 14, 2026after the close | $5.7M+1,250.6% | -$1.08 | -9.2% | -1.2% | 10-Q |
| Q4 2025 | Mar 16, 2026after the close | $22M+1,292.3% | – | -12.8% | +0.2% | 8-K |
Every release
CUE's results days and the share's move after each, from Q3 2019 to Q3 2025, 26 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 8 quarters.
and 21 more, back to Q3 2019
Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one. "With the 10-Q": the quarter was just released and its figures reach the SEC's structured data with the 10-Q, a few weeks later. The press release is linked in the 8-K. Where a 10-Q or 10-K is named, the results came only in that report: the company put out no press release (8-K) for them.
The full analysis
What do Cue Biopharma's filings show?
The results say what Cue Biopharma reported. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.